Drugmakers Mallinckrodt, Endo to Merge, Plan NYSE Listing
1. Mallinckrodt to acquire Endo, creating a $6.7 billion firm. 2. Endo shareholders receive $80 million cash, retain 49.9% stake. 3. Both companies emerged from bankruptcy and face opioid litigation. 4. Merger approved, expected to close by H2 2025. 5. New entity to focus on generics and sterile injectables.